目的 探讨重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)应用于高龄心力衰竭患者的疗效及安全性。方法 选择2012-01至2017-06就诊于解放军总医院心血管内科的慢性心力衰竭急性发作的高龄患者319例,其中常规治疗+ rhBNP181例(rhBNP组),常规治疗138例(对照组)。比较两组患者治疗后5 d、3个月的B型利钠肽前体水平(NT-proBNP),左室射血分数(left ventricular ejection fraction, LVEF),心室短轴缩短指数(left ventricular short axis reduced index, FS),6分钟步行试验(6 minutes walking test, 6MWT),肝、肾功能及血压的变化,以及再住院率的差异。结果 治疗后5 d,rhBNP组中,NT-proBNP显著降低(P<0.05),LVEF、FS及6MWT结果升高(P<0.05)。治疗后3个月,rhBNP组NT-proBNP较对照组明显降低(P<0.05), LVEF、 FS及6MWT较治疗前改善(P<0.05)。rhBNP组与对照组相比,治疗3个月后再住院率显著降低(P<0.05)。结论 rhBNP治疗高龄患者慢性心力衰竭急性加重安全有效,且能降低3个月内因心力衰竭的再住院率。
Abstract
Objective To observe the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) when used in elderly patients.Methods A total of 319 elder patients with heart failure were chosen from our hospital between January 2012 and June 2017.They were randomly divided into the control group (n=138) and rhBNP treatment group (n=181).Patients in both groups were observed and compared in terms of type B natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), ventricular shortening index (FS), the 6-minute walk test (6 MWT), changes of liver function, renal function and blood pressure, and the difference in the rate of re-hospitalization.Results After 5 days, the level of NT-proBNP in the rhBNP treatment group was significantly lower than that in the control group (P<0.05), but LVEF, FS and 6MWT increased (P<0.05). Three months after treatment, the level of NT-proBNP in the rhBNP treatment group was significantly lower than that in the control group (P<0.05), but LVEF, FS and 6MWT improved significantly (P<0.05). After 3 months of treatment, the rate of re-hospitalization in the rhBNP treatment group was significantly lower than that in the control group (P<0.05).Conclusions Recombinant human brain natriuretic peptide (rhBNP) is safe and effective in the treatment of acute exacerbation of chronic heart failure in elderly patients, which can reduce the re-hospitalization rate of heart failure that occurs within 3 months.
关键词
重组人脑利钠肽组 /
高龄患者 /
心力衰竭
Key words
recombinant human brain natriuretic peptide /
elderly people /
heart failure
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Houston B A, Kalathiya R J, Kim D A, et al. Volume overload in heart failure: evidence-based review of strategies for treatment and prevention[J]. Mayo Clin Proc, 2015, 7(16): 196-199.
[2] Lehnart S E, Terrenoire C, Reiken S, et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias[J]. Proc Natl Acad Sci USA, 2006, 103(20): 7906-7910.
[3] Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations, and phosphodiesterase enzymes of the guinea pig[J]. Eur J Pharmacol, 2004, 486(1): 67-74.
[4] Gheorghiade M, Teerlink J R, Mebazaa A. Phamacology of new agents for acute heart failure syndromes[J]. Am J Cardiol, 2005, 96(6A): 68-73.
[5] Lup. A M,Gastelurrutia P,De Antonio M,et al.Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value[J]. Eur J Heart Fail, 2013,15(1): 103-109.
[6] Jourdain P,Jondenu G,Funck F,et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: BNP Multicenter Study[J]. J Am College Cardiol, 2007, 49( 16) : 1733-1739.
[7] 梁菲菲,冀美佳,武俊华.重组人脑利钠肽对慢性心力衰竭患者心功能及心室重构的影响[J]. 海南医学, 2017, 28( 1): 20-23.
[8] 李金英. 慢性心衰患者血浆脑钠肽检测的临床价值[J]. 医学理论与实践, 2017, 30(5): 740-742.
[9] Han B, Li H, Ma Q. Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension [J]. Pak J Pharm Sci, 2017, 30(4): 1449-1453.
[10] Xu H, Wang B, Meng Q,et al. Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure[J]. Pak J Med Sci, 2017, 33(3): 540-544.
[11] Saenger A K, Rodriguez-Fraga O, Ler R, et al. Specificity of B-type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides[J]. Clin Chem, 2017, 63(1):351-358.
[12] He X M, Chen L, Luo J B, et al. Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure[J]. Asian Pac J Trop Med, 2016, 9(8):791-795.
[13] Torres-Courchoud I, Chen H H. B-type natriuretic peptide and acute heart failure: fluid homeostasis, biomarker and therapeutics[J]. Rev Clin Esp, 2016, 216(7): 393-398.
[14] Lanfear D E, Li J, Abbas R, et al. Genetic factors influencing B-type natriuretic peptide-mediated production of cyclic guanosine monophosphate and blood pressure effects in heart failure patients[J]. Cardiovasc Transl Res, 2015, 8(9):545-553.
[15] Zhang Y, Gao F, Zhang X Y, et al. Value of human brain natriuretic peptide in treatment of acute anterior myocardial infarction evaluated via three-dimensional speckle tracking imaging [J]. Genet Mol Res, 2015, 14(2): 5699-5709.
[16] Holditch S J, Schreiber C A, Nini R, et al. B-type natriuretic peptide deletion leads to progressive hypertension, associated organ damage, and reduced survival: novel model for human hypertension[J]. Hypertension, 2015, 66(1):199-210.
[17] Ding Y, Peng Y, Deng L, et al. The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins[J]. Curr Pharm Biotechnol, 2014, 15(9):856-863.
[18] Wang S, Qu X, Qu Y, et al. The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: a randomized controlled clinical trial [J]. Pharmazie, 2014, 69(3): 212-216.
PDF(688 KB)
